Navigation Links
iBio Obtains New IP Protection in China
Date:5/29/2013

NEWARK, Del., May 29, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China. The patent, which will issue from Chinese patent application No.: 200780008098.3, will further broaden the territories in which patent exclusivity has been secured for this novel technology.  In the U.S., the technology is covered by issued U.S. Patent 8,124,103, entitled "Influenza Antigen, Vaccine Compositions, and Related Methods."

(Logo: http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

"China, by virtue of the scale of its rapidly-emerging domestic market and need for new biopharmaceutical technology infrastructure to address influenza and other emerging infectious disease threats, is a target market for us," said Robert Erwin , President of iBio.  "This new intellectual property protection will further facilitate our ability to license our technology for the Chinese market."

The vaccine industry is increasingly focused on the development of recombinant vaccines instead of attenuated, live virus vaccines. These recombinant vaccines commonly require use of components called adjuvants to improve their efficacy. Lichenase protein, when fused to antigens through the use of the iBioModulator technology, acts as an adjuvant and can enhance duration of an immune response, improve production economies and increase product stability in comparison to conventional adjuvant-antigen combinations. Previously published data demonstrated significant improvement in candidate vaccine efficacy in animal models when iBioModulator technology was employed with a range of target antigens, including antigens from plague, malaria, and human papilloma virus.

The iBioModulator platform has been shown to significantly modify the immune response to a vaccine in two important ways. It increases the strength of the initial immune response to a vaccine antigen (as measured by antibody titer). It also extends the duration of the immune response. These results demonstrate that the use of the iBioModulator platform can lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to provide better immune responses and longer-term protection without booster inoculations adds significant value to a vaccine, particularly for use in a market such as China, by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch and iBioModulator™ platforms, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. Additionally, iBio is developing select product candidates that have been derived from the iBioLaunch platform.  The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants.  The iBioModulator platform is complementary to the iBioLaunch platform and is designed to significantly improve vaccine products with both higher potency and greater duration of effect.  The iBioModulator platform can be used with any recombinant expression technology for vaccine development and production. Further information is available at: www.ibioinc.com.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Contacts

Robert Erwin ,
President
302-355-2335
rerwin@ibioinc.com       


'/>"/>
SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
2. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
3. Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
4. AbGenomics International Obtains FDA Agreement on Its Phase 2 Clinical Trial Plans
5. Andrew Technologies Obtains Patent for Visceral Lipectomy Application from USPTO
6. BioElectronics Obtains Additional US Patent For Its Unique Pain Devices
7. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. Broad Patent Protection Granted for iBio Immunomodulator
10. Life Extension Foundation® study finds Cognitex® with NeuroProtection Complex may provide a positive impact on cognitive performance
11. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
(Date:5/10/2017)... , May 10, 2017  The Corporate ... or employees of sleep therapy clinics to call ... sleep therapy clinic is involved in a substantial ... interested in hearing from an employee of a ... in a kickback scheme to provide medical practice groups ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing in ... post on insurance options. If a Bay Area patient has to search for a ... money. Visiting an in-network provider for a second opinion can ensure a patient receives ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells ... Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, ... moved to NYC when she was three. At six, they moved to Dayton, Ohio, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, ... most appropriate instruments for research and understanding the basic principles that were designed ... focus on innovations in stereo microscopy for brightfield and fluorescence typically used in ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and ... now spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation ... Through the program, private practitioners receive cutting-edge clinical training and learn how to ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Myers Jackson is ... has the ability to sell luxury homes anywhere on the planet. The luxury home ... side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction ...
Breaking Medicine News(10 mins):